NORD on the Need for More Collaboration to Drive Progress for Rare Disease Patients

02.17.14 | By

Many biopharmaceutical companies are actively engaged in the research and development of therapies to treat rare disease, despite challenges such as much smaller patient populations than more common diseases. Companies seek opportunities to partner with patient advocacy organizations, academia and the government in order to make even greater progress against rare disease, which collectively affect 1 in 10 Americans.

Test White Papers

03.22.13 | By phrma_admin

Survey of Physicians About Pharmaceutical and Biotech Research Company Activities and Information

Subscribe to RSS - development